eXp World (EXPI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Definitive proxy materials filed for the 2026 Annual Meeting scheduled for April 24, 2026, at 12:00 p.m. Eastern Time.
Key focus is management's proposal to redomesticate from Delaware to Texas, with communications to investors beginning April 22, 2026.
Forward-looking statements address anticipated benefits, risks, and implications of the Texas Redomestication, including legal, regulatory, and financial impacts.
Voting matters and shareholder proposals
Shareholders will vote on the Texas Redomestication proposal at the 2026 Annual Meeting.
The 3% derivative standing threshold is highlighted, aiming to reduce nuisance litigation while preserving avenues for legitimate claims.
Risk oversight and compliance
Risks discussed include legislative, regulatory, and judicial developments, unexpected costs, and litigation outcomes related to the Texas Redomestication.
Potential delays or failure to complete the redomestication due to lack of approvals or stakeholder responses are noted.
Latest events from eXp World
- Shareholders are asked to approve redomestication to Texas, aligning governance with business needs.EXPI
Proxy filing24 Apr 2026 - Shareholders will vote on redomestication to Texas, with key risks and benefits highlighted.EXPI
Proxy filing23 Apr 2026 - Shareholders are voting on a Texas redomestication, with enhanced governance and voting safeguards.EXPI
Proxy filing23 Apr 2026 - Stockholders will vote on redomestication to Texas, aiming for financial and governance benefits.EXPI
Proxy filing22 Apr 2026 - Proxy solicitor engaged for 2026 Annual Meeting to support redomestication vote.EXPI
Proxy filing20 Apr 2026 - Shareholders to vote on Texas redomestication, governance, and compensation changes.EXPI
Proxy Filing9 Mar 2026 - Board recommends approval of director elections, auditor, executive pay, and Texas redomestication.EXPI
Proxy Filing25 Feb 2026 - 2025 revenue rose 4% to $4.8B, with 67% international growth and strong agent productivity.EXPI
Q4 202524 Feb 2026 - Q2 2024 revenue up 5% to $1.3B, adjusted EBITDA up 22%, and $56M returned to shareholders.EXPI
Q2 20242 Feb 2026